Daniel Faga
Chief Executive Officer at ANAPTYSBIO, INC.
Net worth: 9 M $ as of 30/03/2024
Daniel Faga active positions
Companies | Position | Start | End |
---|---|---|---|
ANAPTYSBIO, INC. | Director/Board Member | 25/11/2021 | - |
Chief Executive Officer | 20/03/2022 | - | |
President | 20/03/2022 | - | |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Director/Board Member | 04/04/2022 | - |
Career history of Daniel Faga
Former positions of Daniel Faga
Companies | Position | Start | End |
---|---|---|---|
MIRATI THERAPEUTICS | Chief Operating Officer | 05/01/2020 | 31/10/2021 |
Director of Finance/CFO | 05/01/2020 | 31/10/2021 | |
SPARK THERAPEUTICS, INC. | Corporate Officer/Principal | 03/05/2016 | 30/11/2019 |
Centerview Partners LLC
Centerview Partners LLC Investment Banks/BrokersFinance Centerview Partners LLC is a registered broker/dealer headquartered in New York City. The firm was founded by Robert Pruzan in 2006 and is a subsidiary of Centerview Partners Advisory Holdings LLC. Centerview Partners provides brokerage services to companies, institutions and governments. | Corporate Officer/Principal | 30/06/2009 | 31/03/2016 |
Training of Daniel Faga
Cornell University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
United States | 8 |
Operational
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ANAPTYSBIO, INC. | Health Technology |
Private companies | 4 |
---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Centerview Partners LLC
Centerview Partners LLC Investment Banks/BrokersFinance Centerview Partners LLC is a registered broker/dealer headquartered in New York City. The firm was founded by Robert Pruzan in 2006 and is a subsidiary of Centerview Partners Advisory Holdings LLC. Centerview Partners provides brokerage services to companies, institutions and governments. | Finance |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Daniel Faga
- Experience